Cerebral Array II from Randox Biosciences

Randox Biosciences’ Cerebral Array II has been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The array harnesses multiplex testing measuring up to five biomarkers simultaneously using a single patient sample with a turnaround time of 2.5 hours. It is suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Our Cerebral Array II offers excellent sensitivity, precision and recovery as well as analytical performance.

Cerebral Array II

• C-Reactive Protein (CRP)
• D-Dimer
• Neuron Specific Enolase (NSE)
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Soluble Tumour Necrosis Factor Receptor I (sTNFRI)

Key Benefits of Cerebral Array II

• Multiplex testing from a single sample
• Suitable for human serum, plasma and cerebrospinal fluid (CSF) samples
• Small sample volume
• Excellent analytical performance
• Fast throughput
• Applicable to fully automated and semi-automated Evidence platforms

Your central nervous system is your body’s control centre which includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your senses to the muscles throughout your body. When this is damaged, triggered by an illness or injury it can disturb many functions including memory, sensation and even a person’s personality.¹ Up to 1 billion people (1 in 6 of the world’s population) suffer from neurological disorders from Alzheimer and Parkinson Disease, strokes, multiple sclerosis and epilepsy.²

World Health Organisation (WHO) categorizes neurological disorders in two groups which is shown in the table below³. Group one is classified as neurological disorders in neuropsychiatry which are non-communicable diseases (NCD). NCD is a disease that is not transmissible directly from one person to another. Group two are disorders/injuries with neurological sequelae meaning a pathological condition resulting from a prior disease, injury, or attack.

GROUP ONE	GROUP TWO
Epilepsy	Cerebrovascular disease
Alzheimer and Other Dementias	Neuroinfectious
Parkinson’s Disease	Nutritional deficiencies and neuropathies
Multiple Sclerosis	Neurological injuries
Migraine

Randox Biosciences can assist in cerebrovascular research by providing innovative diagnostic technology and tests that will continue to revolutionise the healthcare industry and assist in academic research. This technology includes our Evidence Investigator and our Cerebral Array II which can be used to assist in the discovery and research of Cerebral diseases.

Biochip Technology

Biochip Technology is an immunoassay testing platform and is the core of Randox Biosciences. The intelligent chemically activated 9x9mm ceramic biochip acts as a solid phase reaction vessel. Benefits of Biochip Technology include:

• The biochips are pre-fabricated with discrete test regions (DTR’s)
• Highly accurate testing
• Better diagnosis
• Reduced sample volume
• Wide test menu
• Multiple sample types can be used on a Biochip
• Cost consolidation

Evidence Investigator

The Evidence Investigator offers a high throughput even as a compact, semi-automated analyser promoting lab efficiency and cost saving solutions. Utilising Randox’s patented Biochip Technology, this platform facilitates multiplex testing in a rapid, accurate and easy-to-use format providing a comprehensive patient profile from one single sample. This analyser is suitable for medium throughput laboratories and is extremely robust with only one moving part.

For further information on our Cerebral Array please visit the Randox Biosciences website.

For any other enquiries please email info@randoxbiosciences.com

References:

1. https://www.healthline.com/health/brain-disorders#types
2. https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report
3. https://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf